Our clinical research activities include genetic, imaging (such as PET/MRI), electrophysiological and biomarker studies, as well as phase I-III clinical trials. Our basic research focuses on the generation of patient-derived stem cell models for ALS and FTD to study disease mechanisms. We also use these models to identify and validate molecular targets for new treatments.
Contact
LocationHerestraat 49, 3000 Leuven, Belgium
Specialists
Current trials
In preparation
Phase iii
The Lighthouse 2 trial
Investigator initiated trial
The Lighthouse 2 study is a phase 3 clinical trial in which we will investigate the efficacy of the drug Triumeq.
In preparation
Phase iii
MAGNET
Platform trial
MAGNET is an innovative clinical platform trial in which multiple treatments for ALS are investigated simultaneously.
Recruiting
Phase iii
TUDCA-ALS (TUDCA)
Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.